Company intelligence / Profile preview

EndoChoice

Atlanta, Georgia, United Statesprnewswire.com ↗

Ownership: Private
Development stage: Commercial

Overview

EndoChoice developed and commercialized innovative endoscopic imaging systems, devices, infection control products, and pathology services for gastroenterology. Its flagship product was the Full Spectrum Endoscope (Fuse®), which offered enhanced visualization during colonoscopies. The company served over 2,500 customers in the US and had distribution partners in 30 countries before being acquired by Boston Scientific in late 2016[5][7].

Therapeutic areas: GastroenterologyOncology
Modalities: DevicePathology servicesInfection control products
Industry: Medical Imaging

Beyond the preview

Go deeper on EndoChoice.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EndoChoice.

Explore the full profile